{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:09Z","timestamp":1793289729972,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Dr. Falk Pharma GmbH"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jhep.2020.09.011","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T06:21:54Z","timestamp":1600323714000},"page":"321-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-2255","authenticated-orcid":false,"given":"Gideon M.","family":"Hirschfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-7799","authenticated-orcid":false,"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limas","family":"Kupcinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martti","family":"F\u00e4rkkil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-0389","authenticated-orcid":false,"given":"Michael","family":"Stiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Greinwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Pr\u00f6ls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Wendum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Drebber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.09.011_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.09.011_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jhep.2020.09.011_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib4","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.09.011_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.011_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.09.011_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.09.011_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.011_bib9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.09.011_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.011_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.09.011_bib12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib15","first-page":"695","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells","volume":"118","author":"Arenas","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2020.09.011_bib16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.011_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0016-5085(93)90037-D","article-title":"The nomenclature of chronic active hepatitis: an obituary","volume":"105","author":"Ludwig","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.09.011_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Pares","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.09.011_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2020.09.011_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2036.1997.tb00814.x","article-title":"Drug development in inflammatory bowel disease: budesonide - a model of targeted therapy","volume":"11","author":"Hamedani","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.09.011_bib23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.09.011_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.09.011_bib25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1365-2036.2006.03155.x","article-title":"Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis","volume":"24","author":"Rautiainen","year":"2006","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820336230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820336230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:40:00Z","timestamp":1759174800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820336230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0168827820336230"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}